
Lei Yao
Examiner (ID: 12775, Phone: (571)272-3112 , Office: P/1642 )
| Most Active Art Unit | 1642 |
| Art Unit(s) | 1642 |
| Total Applications | 1328 |
| Issued Applications | 662 |
| Pending Applications | 127 |
| Abandoned Applications | 552 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 5457862
[patent_doc_number] => 20090258014
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-10-15
[patent_title] => 'COMBINATION OF HGF INHIBITOR AND EGF INHIBITOR TO TREAT CANCER'
[patent_app_type] => utility
[patent_app_number] => 12/421556
[patent_app_country] => US
[patent_app_date] => 2009-04-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 10185
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0258/20090258014.pdf
[firstpage_image] =>[orig_patent_app_number] => 12421556
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/421556 | COMBINATION OF HGF INHIBITOR AND EGF INHIBITOR TO TREAT CANCER | Apr 8, 2009 | Abandoned |
Array
(
[id] => 4629115
[patent_doc_number] => 08007997
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2011-08-30
[patent_title] => 'Methods and compositions for inhibiting the growth of hematopoietic malignant cells'
[patent_app_type] => utility
[patent_app_number] => 12/420676
[patent_app_country] => US
[patent_app_date] => 2009-04-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 33
[patent_figures_cnt] => 44
[patent_no_of_words] => 17900
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/08/007/08007997.pdf
[firstpage_image] =>[orig_patent_app_number] => 12420676
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/420676 | Methods and compositions for inhibiting the growth of hematopoietic malignant cells | Apr 7, 2009 | Issued |
Array
(
[id] => 6371309
[patent_doc_number] => 20100075342
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-03-25
[patent_title] => 'Biomarker for ovarian cancer CTAP3-related proteins'
[patent_app_type] => utility
[patent_app_number] => 12/384246
[patent_app_country] => US
[patent_app_date] => 2009-04-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 16192
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0075/20100075342.pdf
[firstpage_image] =>[orig_patent_app_number] => 12384246
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/384246 | Biomarker for ovarian cancer CTAP3-related proteins | Apr 1, 2009 | Abandoned |
Array
(
[id] => 5928921
[patent_doc_number] => 20110038880
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-02-17
[patent_title] => 'PARASPORIN-1 RECEPTOR AND USE THEREOF'
[patent_app_type] => utility
[patent_app_number] => 12/935513
[patent_app_country] => US
[patent_app_date] => 2009-03-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 9685
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 11
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0038/20110038880.pdf
[firstpage_image] =>[orig_patent_app_number] => 12935513
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/935513 | PARASPORIN-1 RECEPTOR AND USE THEREOF | Mar 29, 2009 | Abandoned |
Array
(
[id] => 5533525
[patent_doc_number] => 20090233313
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-09-17
[patent_title] => 'QUANTIFICATION AND AFFINITY CHARACTERIZATION OF ANTIBODIES FOR THE DIAGNOSIS OF DISEASE USING OPTICAL DIFFRACTION'
[patent_app_type] => utility
[patent_app_number] => 12/402009
[patent_app_country] => US
[patent_app_date] => 2009-03-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 5970
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0233/20090233313.pdf
[firstpage_image] =>[orig_patent_app_number] => 12402009
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/402009 | QUANTIFICATION AND AFFINITY CHARACTERIZATION OF ANTIBODIES FOR THE DIAGNOSIS OF DISEASE USING OPTICAL DIFFRACTION | Mar 10, 2009 | Abandoned |
Array
(
[id] => 6220592
[patent_doc_number] => 20100055687
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-03-04
[patent_title] => 'Mutations in the BCR-ABL tyrosine kinase associated with resistance to ST1-571'
[patent_app_type] => utility
[patent_app_number] => 12/381448
[patent_app_country] => US
[patent_app_date] => 2009-03-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 36838
[patent_no_of_claims] => 50
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0055/20100055687.pdf
[firstpage_image] =>[orig_patent_app_number] => 12381448
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/381448 | Mutations in the Bcr-Abl tyrosine kinase associated with resistance to ST1-571 | Mar 10, 2009 | Issued |
Array
(
[id] => 6537848
[patent_doc_number] => 20100221709
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-09-02
[patent_title] => 'METHODS FOR IDENTIFYING AGENTS THAT MODULATE APOPTOSIS IN CELLS THAT OVER-EXPRESS A BCL-2 FAMILY MEMBER PROTEIN'
[patent_app_type] => utility
[patent_app_number] => 12/400717
[patent_app_country] => US
[patent_app_date] => 2009-03-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 18
[patent_no_of_words] => 31806
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0221/20100221709.pdf
[firstpage_image] =>[orig_patent_app_number] => 12400717
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/400717 | METHODS FOR IDENTIFYING AGENTS THAT MODULATE APOPTOSIS IN CELLS THAT OVER-EXPRESS A BCL-2 FAMILY MEMBER PROTEIN | Mar 8, 2009 | Abandoned |
Array
(
[id] => 9060100
[patent_doc_number] => 08546535
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2013-10-01
[patent_title] => 'Lytic domain fusion constructs and methods of making and using same'
[patent_app_type] => utility
[patent_app_number] => 12/398965
[patent_app_country] => US
[patent_app_date] => 2009-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 32
[patent_no_of_words] => 29389
[patent_no_of_claims] => 57
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12398965
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/398965 | Lytic domain fusion constructs and methods of making and using same | Mar 4, 2009 | Issued |
Array
(
[id] => 5534072
[patent_doc_number] => 20090233860
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-09-17
[patent_title] => 'LYTIC DOMAIN FUSION CONSTRUCTS AND METHODS OF MAKING AND USING SAME'
[patent_app_type] => utility
[patent_app_number] => 12/398958
[patent_app_country] => US
[patent_app_date] => 2009-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 23
[patent_no_of_words] => 28873
[patent_no_of_claims] => 55
[patent_no_of_ind_claims] => 34
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0233/20090233860.pdf
[firstpage_image] =>[orig_patent_app_number] => 12398958
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/398958 | LYTIC DOMAIN FUSION CONSTRUCTS AND METHODS OF MAKING AND USING SAME | Mar 4, 2009 | Abandoned |
Array
(
[id] => 8270507
[patent_doc_number] => 08212010
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2012-07-03
[patent_title] => 'Sphingosine 1-phosphate antagonism'
[patent_app_type] => utility
[patent_app_number] => 12/391664
[patent_app_country] => US
[patent_app_date] => 2009-02-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16812
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 9
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12391664
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/391664 | Sphingosine 1-phosphate antagonism | Feb 23, 2009 | Issued |
Array
(
[id] => 5473615
[patent_doc_number] => 20090246781
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-10-01
[patent_title] => 'Method for early determination of recurrence after therapy for prostate cancer'
[patent_app_type] => utility
[patent_app_number] => 12/378965
[patent_app_country] => US
[patent_app_date] => 2009-02-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 25
[patent_figures_cnt] => 25
[patent_no_of_words] => 18732
[patent_no_of_claims] => 113
[patent_no_of_ind_claims] => 47
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0246/20090246781.pdf
[firstpage_image] =>[orig_patent_app_number] => 12378965
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/378965 | Method for early determination of recurrence after therapy for prostate cancer | Feb 18, 2009 | Abandoned |
Array
(
[id] => 6031004
[patent_doc_number] => 20110081350
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-04-07
[patent_title] => 'Synthetic scFv Analogue To The 6313/G2 (Anti Angiotensin II Type 1 Receptor) Monoclonal Antibody Variable Regions'
[patent_app_type] => utility
[patent_app_number] => 12/867911
[patent_app_country] => US
[patent_app_date] => 2009-02-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 15
[patent_no_of_words] => 10166
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0081/20110081350.pdf
[firstpage_image] =>[orig_patent_app_number] => 12867911
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/867911 | Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal antibody variable regions | Feb 17, 2009 | Issued |
Array
(
[id] => 10857770
[patent_doc_number] => 08883972
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2014-11-11
[patent_title] => 'High specificity monoclonal antibody against a protein or a polypeptide having oxidative modification'
[patent_app_type] => utility
[patent_app_number] => 12/379084
[patent_app_country] => US
[patent_app_date] => 2009-02-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 9231
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12379084
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/379084 | High specificity monoclonal antibody against a protein or a polypeptide having oxidative modification | Feb 11, 2009 | Issued |
Array
(
[id] => 5485754
[patent_doc_number] => 20090275519
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-11-05
[patent_title] => 'Therapeutic peptidomimetic macrocycles'
[patent_app_type] => utility
[patent_app_number] => 12/378047
[patent_app_country] => US
[patent_app_date] => 2009-02-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 56
[patent_figures_cnt] => 56
[patent_no_of_words] => 34626
[patent_no_of_claims] => 87
[patent_no_of_ind_claims] => 7
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0275/20090275519.pdf
[firstpage_image] =>[orig_patent_app_number] => 12378047
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/378047 | Therapeutic peptidomimetic macrocycles | Feb 8, 2009 | Abandoned |
Array
(
[id] => 6588913
[patent_doc_number] => 20100062003
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-03-11
[patent_title] => 'THERAPEUTIC AND DIAGNOSTIC APPLICATIONS BASED ON THE ROLE OF THE CXCR-4 GENE IN TUMORIGENESIS'
[patent_app_type] => utility
[patent_app_number] => 12/367308
[patent_app_country] => US
[patent_app_date] => 2009-02-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 25
[patent_figures_cnt] => 25
[patent_no_of_words] => 31041
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 13
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0062/20100062003.pdf
[firstpage_image] =>[orig_patent_app_number] => 12367308
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/367308 | Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis | Feb 5, 2009 | Issued |
Array
(
[id] => 5485843
[patent_doc_number] => 20090275608
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-11-05
[patent_title] => 'Methods of diagnosing and treating parp-mediated diseases'
[patent_app_type] => utility
[patent_app_number] => 12/322551
[patent_app_country] => US
[patent_app_date] => 2009-02-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 24
[patent_figures_cnt] => 24
[patent_no_of_words] => 77775
[patent_no_of_claims] => 75
[patent_no_of_ind_claims] => 10
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0275/20090275608.pdf
[firstpage_image] =>[orig_patent_app_number] => 12322551
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/322551 | Methods of diagnosing and treating parp-mediated diseases | Feb 3, 2009 | Abandoned |
Array
(
[id] => 6024175
[patent_doc_number] => 20110052501
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-03-03
[patent_title] => 'POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS'
[patent_app_type] => utility
[patent_app_number] => 12/863189
[patent_app_country] => US
[patent_app_date] => 2009-02-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 99
[patent_figures_cnt] => 99
[patent_no_of_words] => 129324
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0052/20110052501.pdf
[firstpage_image] =>[orig_patent_app_number] => 12863189
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/863189 | POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS | Jan 31, 2009 | Abandoned |
Array
(
[id] => 6196053
[patent_doc_number] => 20110027811
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-02-03
[patent_title] => 'ASSAY SYSTEM FOR THE ASSESSMENT OF ONCOGENICITY, TUMOR PROGRESSION, AND TREATMENT EFFICACY'
[patent_app_type] => utility
[patent_app_number] => 12/864185
[patent_app_country] => US
[patent_app_date] => 2009-01-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 4578
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0027/20110027811.pdf
[firstpage_image] =>[orig_patent_app_number] => 12864185
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/864185 | Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy | Jan 25, 2009 | Issued |
Array
(
[id] => 8543607
[patent_doc_number] => 08318899
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2012-11-27
[patent_title] => 'Lytic domain fusion constructs and methods of making and using same'
[patent_app_type] => utility
[patent_app_number] => 12/359906
[patent_app_country] => US
[patent_app_date] => 2009-01-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 32
[patent_no_of_words] => 29294
[patent_no_of_claims] => 43
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12359906
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/359906 | Lytic domain fusion constructs and methods of making and using same | Jan 25, 2009 | Issued |
Array
(
[id] => 5434984
[patent_doc_number] => 20090169570
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-07-02
[patent_title] => 'METHODS AND AGENTS FOR IMPROVING TARGETING OF CD138 EXPRESSING TUMOR CELLS'
[patent_app_type] => utility
[patent_app_number] => 12/342815
[patent_app_country] => US
[patent_app_date] => 2008-12-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 21
[patent_no_of_words] => 29826
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0169/20090169570.pdf
[firstpage_image] =>[orig_patent_app_number] => 12342815
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/342815 | Methods and agents for improving targeting of CD138 expressing tumor cells | Dec 22, 2008 | Issued |